News

August 21, 2017August 21, 2017

American Society of Clinical Oncology Updates Guidelines for Treatment of Advanced Non-Small Cell Lung Cancer

The American Society of Clinical Oncology (ASCO) recently updated its clinical guidelines for advanced non-small cell lung cancer (NSCLC) so that oncologists can select the most appropriate treatment for patients. Treatments ... Read more

August 19, 2017

First Patient with BPDCN Receives UCART123 Dose in Phase 1 Clinical Trial

News

The first patient with Blastic Plasmacytoid Dendritic Cell Neoplasms (BPDCN) has received a dose of Cellectis’ UCART123 in a Phase 1 clinical trial. UCART123 is a gene edited T-cell drug ... Read more

August 18, 2017August 18, 2017

Scientists Examine How Anti-CTLA-4 and Anti-PD-1 Checkpoint-Blockade Therapies Fight Cancer Cells

News

Researchers have known that the checkpoint blockade therapies CTLA-4 and PD-1 inhibitors have been clinically successful in treating cancer patients. But they didn’t fully understand how these inhibitors function. ... Read more

August 17, 2017August 17, 2017

Opdivo and Yervoy Combo Seen to Outperform Sutent in Untreated Advanced Kidney Cancer, But More Data Needed

News

The combination of Opdivo (nivolumab) and Yervoy (ipilimumab) was more effective in fighting advanced kidney cancer in previously untreated patients than the approved therapy Sutent (sunitinib), Bristol-Meyers Squibb reported after analyzing ... Read more

August 16, 2017August 16, 2017

Brain Cancer Vaccine SurVaxM Receives FDA Orphan Drug Status

News

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to SurVaxM, an immunotherapy treatment developed at the Roswell Park Cancer Institute for a type of brain cancer called glioblastoma. ... Read more

August 14, 2017August 14, 2017

New Immuno-Oncology Therapy Against Advanced Solid Tumors to Enter Phase 1 Clinical Studies

News

An experimental immuno-oncology treatment will move into early phase clinical trials for patients with advanced solid tumors, under a collaboration agreement between Cancer Research UK and Biotecnol. The therapy, called Tb535H, is a T-cell engager ... Read more

August 10, 2017

Dozens of New Genes with Resistance to Cancer Immunotherapy Discovered

News

Researchers have identified dozens of new genes associated with resistance to anti-cancer immunotherapies, shedding light on ways to overcome such resistance. The study, “Identification of essential genes for cancer ... Read more

August 4, 2017

FDA Approves Opdivo for Two Metastatic Colorectal Cancers That Failed to Respond to Chemo

News

The U.S. Food and Drug Administration has approved the immunotherapy Opdivo (nivolumab) as a treatment for two colorectal cancers that failed to respond to a chemotherapy combination, according to its developer, Bristol-Myers Squibb. Opdivo ... Read more

August 3, 2017

FDA Grants Breakthrough Therapy Status to Imfinzi for Unresectable NSCLC

News

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to Imfinzi (durvalumab) for patients with locally advanced, unresectable (unable to be removed with surgery) non-small cell lung cancer ... Read more

August 1, 2017

Natural Killer Cells Are Important to Ceplene’s Ability to Keep Leukemia in Remission, Trial Shows

News

An immune system component known as natural killer cells is crucial for a combination of Ceplene and interleukin-2 to keep acute myeloid leukemia in remission, according to a Phase 4 clinical ... Read more